image
Healthcare - Biotechnology - OTC - US
$ 0.7
5.21 %
$ 1.87 M
Market Cap
0.13
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one VCNX stock under the worst case scenario is HIDDEN Compared to the current market price of 0.7 USD, Vaccinex, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one VCNX stock under the base case scenario is HIDDEN Compared to the current market price of 0.7 USD, Vaccinex, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one VCNX stock under the best case scenario is HIDDEN Compared to the current market price of 0.7 USD, Vaccinex, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart VCNX

image
$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0$0.5$0.5$0.0$0.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
601 K REVENUE
5.44%
-18.7 M OPERATING INCOME
18.13%
-18.6 M NET INCOME
7.98%
-16.2 M OPERATING CASH FLOW
6.08%
-22 K INVESTING CASH FLOW
67.16%
15.8 M FINANCING CASH FLOW
26.80%
52 K REVENUE
-77.59%
-4.55 M OPERATING INCOME
20.45%
-5.73 M NET INCOME
-1.79%
-3.21 M OPERATING CASH FLOW
27.36%
-8 K INVESTING CASH FLOW
42.86%
5.89 M FINANCING CASH FLOW
248.40%
Balance Sheet Vaccinex, Inc.
image
Current Assets 2.53 M
Cash & Short-Term Investments 1.11 M
Receivables 838 K
Other Current Assets 586 K
Non-Current Assets 65 K
Long-Term Investments 0
PP&E 65 K
Other Non-Current Assets 0
42.64 %32.28 %22.57 %Total Assets$2.6m
Current Liabilities 5.08 M
Accounts Payable 3.96 M
Short-Term Debt 25 K
Other Current Liabilities 1.1 M
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
77.79 %21.72 %Total Liabilities$5.1m
EFFICIENCY
Earnings Waterfall Vaccinex, Inc.
image
Revenue 601 K
Cost Of Revenue 0
Gross Profit 601 K
Operating Expenses 19.3 M
Operating Income -18.7 M
Other Expenses -101 K
Net Income -18.6 M
2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)(18m)(18m)(20m)(20m)601k0601k(19m)(19m)101k(19m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-3117.30% OPERATING MARGIN
-3117.30%
-3100.50% NET MARGIN
-3100.50%
748.95% ROE
748.95%
-717.80% ROA
-717.80%
760.66% ROIC
760.66%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Vaccinex, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -18.6 M
Depreciation & Amortization 94 K
Capital Expenditures -22 K
Stock-Based Compensation 341 K
Change in Working Capital 0
Others 2.01 M
Free Cash Flow -16.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Vaccinex, Inc.
image
VCNX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Vaccinex, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
1.32 M USD 1
6-9 MONTHS
9.21 K USD 1
9-12 MONTHS
7. News
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. Pepinemab, Semaphorin 4D blocking immunotherapy, also appears to induce the formation of efficient lymphoid structures in “cold” tumors of patients with recurrent and metastatic head and neck cancer. globenewswire.com - 1 week ago
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market (“Nasdaq”) of its decision to delist the Company's shares of common stock, par value $0.0001 per share (the “Common Stock”), from Nasdaq. Trading in the Common Stock on Nasdaq has been suspended since December 18, 2024. globenewswire.com - 1 month ago
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update Actively Exploring Partnership for Alzheimer's Development Supplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced financial results for the third quarter ended September 30, 2024 and provided a corporate update on its key program for Alzheimer's disease. globenewswire.com - 5 months ago
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC Partnerships will employ Vaccinex's ActivMAb® tech. Successful antibody discovery campaigns for cancer immunotherapy to be presented at SITC Nov 9, 2024. globenewswire.com - 5 months ago
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting Pepinemab appears to enhance clinical activity of immune checkpoint inhibitors via induction of mature tertiary lymphoid structures in tumors of patients with HPV-negative head and neck cancer. Pepinemab appears to enhance clinical activity of immune checkpoint inhibitors via induction of mature tertiary lymphoid structures in tumors of patients with HPV-negative head and neck cancer. globenewswire.com - 5 months ago
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain Company describes new biomarker and cognitive treatment effects that support continued development of pepinemab in Mild Cognitive Impairment and Mild Dementia due to Alzheimer's disease Company describes new biomarker and cognitive treatment effects that support continued development of pepinemab in Mild Cognitive Impairment and Mild Dementia due to Alzheimer's disease globenewswire.com - 6 months ago
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, announced today the entry into definitive agreements for the immediate exercise of outstanding warrants to purchase an aggregate of 1,067,492 shares of common stock (the “Existing Warrants”) at the reduced exercise price of $5.636 per share, resulting in the issuance of 827,483 shares and the pre-funding of 240,009 shares. globenewswire.com - 7 months ago
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership ROCHESTER, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease. globenewswire.com - 8 months ago
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's Disease Company expects to lock database in June andremains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation,believed to be key drivers of neurodegeneration. globenewswire.com - 10 months ago
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update Last patient last visit in SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer's Disease in early June 2024. $8.2 million of new financing in Q1. globenewswire.com - 11 months ago
Vaccinex Reports 2023 Financial Results and Provides Corporate Update Expect Topline Data for Randomized SIGNAL-AD Study of Pepinemab for Alzheimer's Disease in Q3 2024. $17.9 million of new financing in Q4 2023 and Q1 2024. globenewswire.com - 1 year ago
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease and cancer through the inhibition of SEMA4D, today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of 193,000 shares of its common stock in a registered direct offering together with warrants to purchase up to an aggregate of 193,000 shares of common stock in a concurrent private placement priced at-the-market under Nasdaq rules at a combined purchase price of $7.77 per share and accompanying warrant. The warrants will have an exercise price of $7.64 per share, will be immediately exercisable upon issuance and will expire 5 years from the initial exercise date. The registered direct offering and concurrent private placement are referred to herein as the “Transactions.” globenewswire.com - 1 year ago
8. Profile Summary

Vaccinex, Inc. VCNX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 1.87 M
Dividend Yield 0.00%
Description Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Contact 1895 Mount Hope Avenue, Rochester, NY, 14620 https://www.vaccinex.com
IPO Date Aug. 9, 2018
Employees 23
Officers Dr. Maurice Zauderer Ph.D. Co-Founder, Chief Executive Officer, President & Director Dr. Elizabeth E. Evans Ph.D. Chief Operating Officer and Senior Vice President of Discovery & Translational Medicine Dr. Ernest S. Smith Ph.D. Senior Vice President of Research & Chief Scientific Officer